Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Nykode Therapeutics

Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the next trial in Advanced Cervical Cancer
From Nykode Therapeutics
Via GlobeNewswire
Nykode Therapeutics to Present at Jefferies Healthcare Conference
From Nykode Therapeutics
Via GlobeNewswire
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer
From Nykode Therapeutics
Via GlobeNewswire
Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023
From Nykode Therapeutics
Via GlobeNewswire
Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer
From Nykode Therapeutics
Via GlobeNewswire
Nykode Therapeutics to Present at SVB Securities Global Biopharma Conference
From Nykode Therapeutics
Via GlobeNewswire
Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Nykode Therapeutics
Via GlobeNewswire
Nykode announces expanded clinical development plan for its lead cancer vaccine VB10.16 in HPV16-positive cancers
From Nykode Therapeutics
Via GlobeNewswire
Nykode Therapeutics and Richter-Helm BioLogics Announce Strategic Manufacturing Partnership
From Nykode Therapeutics
Via GlobeNewswire
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer
From Nykode Therapeutics
Via GlobeNewswire
Nykode Therapeutics to announce financial results for the third quarter 2022 and host webcast presentation on November 23, 2022
From Nykode Therapeutics
Via GlobeNewswire
Nykode Therapeutics presents additional efficacy analysis in Phase 2 study of VB10.16 in combination with atezolizumab in advanced cervical cancer
From Nykode Therapeutics
Via GlobeNewswire
Nykode Therapeutics to present at two upcoming investor conferences in November
From Nykode Therapeutics
Via GlobeNewswire
Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit
From Nykode Therapeutics
Via GlobeNewswire
Vaccibody Becomes Nykode Therapeutics - a New Name and Identity to Signify a New Phase of Growth and Development
From Nykode Therapeutics
Via Business Wire
Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases
From Nykode Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.